Huixian Miao

Huixian Miao

Auto-generated profile, based on publicly available information

Huixian Miao

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
HMHuixian Miao
Huixian Miao
HMHuangyang Meng
Huangyang Meng
YZYashuang Zhang
Yashuang Zhang
TCTian Chen
Tian Chen
LZLin Zhang
Lin Zhang
WCwenjun cheng
wenjun cheng
Poly ADP-ribose polymerase inhibitors (PARPis) exhibit promising efficacy in patients with BRCA mutations or homologous repair deficiency (HRD) in ovarian cancer (OC). However, less than 40% of patients have HRD, it is vital to expand the indications for PARPis in BRCA-proficient patients. Ferroptosis suppressor protein 1 (FSP1) is a key protein in a newly identified ferroptosis-protective mechanism that occurs in parallel with the GPX4-mediated pathway and is associated with chemoresistance in several cancers. Herein, FSP1 is reported to be negatively correlated with the prognosis in OC patients. Combination therapy comprising olaparib and iFSP1 (a FSP1 inhibitor) strongly inhibited tumour proliferation in BRCA-proficient OC cell lines, patient-derived organoids (PDOs) and xenograft mouse models. Surprisingly, the synergistic killing effect could not be reversed by ferroptosis inhibitors, indicating that mechanisms other than ferroptosis were responsible for the synergistic lethality. In addition, cotreatment was shown to induce increased γH2A.X foci and to impair nonhomologous end joining (NHEJ) activity to a greater extent than did any single drug. Mass spectrometry and immunoprecipitation analyses revealed that FSP1 interacted with Ku70, a classical component recruited to and occupying the end of double-strand breaks (DSBs) in the NHEJ process. FSP1 inhibition decreased Ku70 PARylation, impaired subsequent DNA-PKcs recruitment to the Ku complex at DSB sites and was rescued by restoring PARylation. These findings unprecedentedly reveal a novel role of FSP1 in DNA damage repair and provide new insights into how to sensitize OC patients to PARPi treatment.

17 April 2021 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
HMHuixian Miao
Huixian Miao
YCYunyan Chen
Yunyan Chen
CWChuan Wang
Chuan Wang
THTaotao Huang
Taotao Huang
JLJianhua Lin
Jianhua Lin

5 October 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
HMHuixian Miao
Huixian Miao
LZLin Zhang
Lin Zhang
YJYi Jiang
Yi Jiang
YWYicong Wan
Yicong Wan
LYLin Yuan
Lin Yuan
WCwenjun cheng
wenjun cheng

4 November 2020
Verified
Preprint
Open access
HMHuixian Miao
Huixian Miao
JLJianhua Lin
Jianhua Lin
YCYunyan Chen
Yunyan Chen
CWChuan Wang
Chuan Wang
THTaotao Huang
Taotao Huang
In this study, we aim to find out maternal and fetal outcomes in women with PH resulting from different causes and try to determine the risk factors related to adverse maternal and fetal outcomes. We extracted the data from the records: the demographic information, onset, course, clinical and echocardiographic details, maternal and fetal complications, management as well as obstetric data, which included complications, infant of low-birth weight. We compared the outcome based on the cause of disease and pulmonary hypertension pressure levels. 603 women were included in the final analysis, who were mainly had pulmonary hypertension secondary to congenital heart disease (66.0%) and 46 of whom had Eisenmenger syndrome (7.6%). The mortality was 3.0%, 56% of which was caused by Eisenmenger syndrome. The abortion rate was 8.3% and 32% of live newborns were born before term. Heart failure complicated 17.1% and fetal growth restriction 3.5% of pregnancies. Advanced medication was administered in an increasing number of patients. Morbidity was significantly increased in women with pulmonary hypertension associated with a pulmonary hypertension pressure ≥80 mmHg. The mortality rate was lower than previously reported. Nevertheless, in Eisenmenger syndrome, PH secondary to connective tissue disease and idiopathic PH, the maternal mortality is still very high. In addition to the use of PAH-targeted drugs, we believe that standardized maternal management strategies can also help reduce mortality, including screening for heart disease and effective transport of critically ill patients. The maternal and infant outcome is related to etiology and the severity of PASP.

30 January 2024
Verified
Preprint
Open access
PDF file
HMHuixian Miao
Huixian Miao
YCYunyan Chen
Yunyan Chen
CWChuan Wang
Chuan Wang
THTaotao Huang
Taotao Huang
JLJianhua Lin
Jianhua Lin
In this study, we aim to find out maternal and fetal outcomes in women with PH resulting from different causes and try to determine the risk factors related to adverse maternal and fetal outcomes. 684 women were included in the final analysis, who were mainly had pulmonary hypertension secondary to congenital heart disease (65.4%). Patients with idiopathic PH have the highest mortality (35.3%) and the lowest live birth rate (82.4%). Mortality is similar between moderate and severe PH women(5.3% vs 9.7%, P=0.17), but live birth rate is much lower in severe PH women (78.6% vs 89.9%, P<0.01). The overall mortality was 2.8%, decreasing from 6.6% (4/61) in 2001~2005 to 1.7% (4/235) in 2016~2020 (P=0.10). Hypoxemia and vaginal birth are risk factors of maternal death both in the univariate analysis [OR 13.49(5.15-35.31), OR 4.16(1.52-11.42), respectively] and multivariate analysis [35.28 (1.42-878.75), 850.86 (5.67-127606.74), respectively]. General anesthesia is a risk factor in the univariate analysis [OR 12.07(3.72-39.15)] but with no significance in the multivariate analysis (P=0.16). We demonstrate a lower mortality rate than previously reported, although of no statistical difference among years in our center. In PH secondary to connective tissue disease and idiopathic PH, maternal mortality remains high. Maternal and fetal outcome are related to the etiology and the severity of PASP. Hypoxemia is a risk factor of maternal death while cesarean section seems to be a protective factor. The ideal choice of anesthesia remains uncertain. PH-targeted drugs cannot effectively decrease mortality rate. Thus, pregnancies remain challengeable in PH women.